The role of regional chemotherapy in the management of extremity soft tissue malignancies

European Journal of Surgical Oncology

Volumn 42, Issue 1, 2016, Pages 7-17

  Smith, H G ^a   Hayes, A J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

In transit melanoma; Isolated limb infusion; Isolated limb perfusion; Soft tissue sarcoma

Indexed keywords

DACTINOMYCIN; DOXORUBICIN; IPILIMUMAB; MELPHALAN; MONOCLONAL ANTIBODY; NIVOLUMAB; TEMOZOLOMIDE; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT;

ANGIOSARCOMA; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; ELECTROCHEMOTHERAPY; FIBROMATOSIS; HUMAN; ISOLATED LIMB INFUSION; ISOLATED LIMB PERFUSION; LIMB AMPUTATION; LIMB SALVAGE; LIMB TUMOR; MELANOMA; MERKEL CELL TUMOR; METASTATIC MELANOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGIONAL PERFUSION; REVIEW; SOFT TISSUE SARCOMA; SOFT TISSUE TUMOR; SQUAMOUS CELL CARCINOMA; SYSTEMIC CIRCULATION; TREATMENT RESPONSE; EPIDEMIOLOGY; FEMALE; FOLLOW UP; LIMB; MALE; MORTALITY; PATHOLOGY; PROCEDURES; RISK ASSESSMENT; ROLE PLAYING; SARCOMA; SKIN NEOPLASMS; SOFT TISSUE NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; EXTREMITIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MELPHALAN; NEOPLASM RECURRENCE, LOCAL; RISK ASSESSMENT; ROLE; SARCOMA; SKIN NEOPLASMS; SOFT TISSUE NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84953371456     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2015.08.165     Document Type: Review

References (88)

1. H.J. Zeh 3rd, C.K. Brown, M.P. Holtzman, and et al. A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer Ann Surg Oncol 16 2009 385 394
2. S. Bonvalot, J. Muret, and T. Debaere Pelvic perfusion for locally advanced tumors Bull Cancer 96 2009 103 109
3. S. Kunwar, M.D. Prados, S.M. Chang, and et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group J Clin Oncol 25 2007 837 844
4. C.C. Stucky, R.J. Gray, A.C. Dueck, and et al. Risk factors associated with local and in-transit recurrence of cutaneous melanoma Am J Surg 200 2010 770 774 discussion 774-5
5. C.M. Balch, J.E. Gershenwald, S.J. Soong, and et al. Final version of 2009 AJCC melanoma staging and classification J Clin Oncol 27 2009 6199 6206
6. H.S. Koops, M. Vaglini, S. Suciu, and et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer malignant melanoma Cooperative Group protocol 18832, the World Health Organization melanoma Program trial 15, and the North American Perfusion Group Southwest Oncology Group-8593 J Clin Oncol 16 1998 2906 2912
7. F. Ghussen, K. Nagel, W. Groth, and et al. A prospective randomized study of regional extremity perfusion in patients with malignant melanoma Ann Surg 200 1984 764 768
8. L. Hafstrom, C.M. Rudenstam, E. Blomquist, and et al. Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group J Clin Oncol 9 1991 2091 2094
9. J. Gehl Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research Acta Physiol Scand 177 2003 437 447
10. L.G. Campana, S. Valpione, S. Mocellin, and et al. Electrochemotherapy for disseminated superficial metastases from malignant melanoma Br J Surg 99 2012 821 830
11. J.M. Mir-Bonafe, A. Vilalta, I. Alarcon, and et al. Electrochemotherapy in the treatment of melanoma skin metastases: a report on 31 cases Actas Dermosifiliogr 106 2015 285 291
12. F. Ricotti, K. Giuliodori, I. Cataldi, and et al. Electrochemotherapy: an effective local treatment of cutaneous and subcutaneous melanoma metastases Dermatol Ther 27 2014 148 152
13. C. Caraco, N. Mozzillo, U. Marone, and et al. Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis BMC Cancer 13 2013 564
14. B. Mali, D. Miklavcic, L.G. Campana, and et al. Tumor size and effectiveness of electrochemotherapy Radiol Oncol 47 2013 32 41
15. J. Huang, and W.J. Mackillop Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma Cancer 92 2001 172 180
16. F.W. Stewart, and N. Treves Lymphangiosarcoma in postmastectomy lymphedema; a report of six cases in elephantiasis chirurgica Cancer 1 1948 64 81
17. P. Roy, M.A. Clark, and J.M. Thomas Stewart-Treves syndrome-treatment and outcome in six patients from a single centre Eur J Surg Oncol 30 2004 982 986
18. T.E. Lans, J.H. de Wilt, A.N. van Geel, and et al. Isolated limb perfusion with tumor necrosis factor and melphalan for nonresectable Stewart-Treves lymphangiosarcoma Ann Surg Oncol 9 2002 1004 1009
19. M.E. Spurgeon, and P.F. Lambert Merkel cell polyomavirus: a newly discovered human virus with oncogenic potential Virology 435 2013 118 130
20. M.H. Swann, and J. Yoon Merkel cell carcinoma Semin Oncol 34 2007 51 56
21. C.K. Bichakjian, T. Olencki, M. Alam, and et al. Merkel cell carcinoma, version 1.2014 J Natl Compr Canc Netw 12 2014 410 424
22. N.C. Zeitouni, C.N. Giordano, and J.M. Kane III In-transit Merkel cell carcinoma treated with isolated limb perfusion or isolated limb infusion: a case series of 12 patients Dermatol Surg 37 2011 357 364
23. A. Gronchi, P.G. Casali, L. Mariani, and et al. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution J Clin Oncol 21 2003 1390 1397
24. S. Bonvalot, H. Eldweny, V. Haddad, and et al. Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients Eur J Surg Oncol 34 2008 462 468
25. D.L. van Broekhoven, J.P. Deroose, S. Bonvalot, and et al. Isolated limb perfusion using tumour necrosis factor alpha and melphalan in patients with advanced aggressive fibromatosis Br J Surg 101 2014 1674 1680
26. A.M. Eggermont, H. Schraffordt Koops, J.M. Klausner, and et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience Ann Surg 224 1996 756 764 discussion 764-5
27. A. Gronchi, S. Lo Vullo, C. Colombo, and et al. Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival Ann Surg 251 2010 506 511
28. P.W. O'Donnell, A.M. Griffin, W.C. Eward, and et al. The effect of the setting of a positive surgical margin in soft tissue sarcoma Cancer 120 2014 2866 2875
29. J. Jakob, P.U. Tunn, A.J. Hayes, and et al. Oncological outcome of primary non-metastatic soft tissue sarcoma treated by neoadjuvant isolated limb perfusion and tumor resection J Surg Oncol 109 2014 786 790
30. O. Creech Jr., E.T. Krementz, R.F. Ryan, and et al. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit Ann Surg 148 1958 616 632
31. G. Omlor, G. Gross, K.W. Ecker, and et al. Optimization of isolated hyperthermic limb perfusion World J Surg 16 1992 1117 1119
32. P.J. Bryant, G.A. Balderson, P. Mead, and et al. Hyperthermic isolated limb perfusion for malignant melanoma: response and survival World J Surg 19 1995 363 368
33. B.B.R. Kroon, J.M. Klaase, A.N. Van Geel, and A.M.M. Eggermont Application of hyperthermia in regional isolated perfusion for melanoma of the limbs Reg Cancer Treat 4 1992 223 226
34. J.F. Thompson, R.C. Waugh, R.P. Saw, and P.C. Kam Isolated limb infusion (ILI) with melphalan for recurrent limb melanoma Reg Cancer Treat 6 1993 51 52
35. D.W. Siemann, M. Chapman, and A. Beikirch Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy Int J Radiat Oncol Biol Phys 20 1991 287 289
36. A.A. Santillan, K.A. Delman, G.M. Beasley, and et al. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis Ann Surg Oncol 16 2009 2570 2578
37. J. Hansson, R. Lewensohn, U. Ringborg, and et al. Formation and removal of DNA cross-links induced by melphalan and nitrogen mustard in relation to drug-induced cytotoxicity in human melanoma cells Cancer Res 47 1987 2631 2637
38. J. Wieberdink, C. Benckhuysen, R.P. Braat, and et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions Eur J Cancer Clin Oncol 18 1982 905 910
39. H.M. Sobell Actinomycin and DNA transcription Proc Natl Acad Sci U. S. A 82 1985 5328 5331
40. C.R. Rossi, M. Foletto, F. Di Filippo, and et al. Soft tissue limb sarcomas: Italian clinical trials with hyperthermic antiblastic perfusion Cancer 86 1999 1742 1749
41. C.J. Wray, R.S. Benjamin, K.K. Hunt, and et al. Isolated limb perfusion for unresectable extremity sarcoma: results of 2 single-institution phase 2 trials Cancer 117 2011 3235 3241
42. T. Ueno, S.H. Ko, E. Grubbs, and et al. Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine Mol Cancer Ther 5 2006 732 738
43. Y. Yoshimoto, C.K. Augustine, J.S. Yoo, and et al. Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents Mol Cancer Ther 6 2007 1492 1500
44. G.M. Beasley, P. Speicher, C.K. Augustine, and et al. A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion Ann Surg Oncol 22 2015 287 294
45. E.A. Carswell, L.J. Old, R.L. Kassel, and et al. An endotoxin-induced serum factor that causes necrosis of tumors Proc Natl Acad Sci U. S. A 72 1975 3666 3670
46. T. Tjardes, and E. Neugebauer Sepsis research in the next millennium: concentrate on the software rather than the hardware Shock 17 2002 1 8
47. F.R. Balkwill, A. Lee, G. Aldam, and et al. Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons Cancer Res 46 1986 3990 3993
48. J.L. Abbruzzese, B. Levin, J.A. Ajani, and et al. Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer Cancer Res 49 1989 4057 4061
49. D. Lienard, P. Ewalenko, J.J. Delmotte, and et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma J Clin Oncol 10 1992 52 60
50. J.H. de Wilt, T.L. ten Hagen, G. de Boeck, and et al. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion Br J Cancer 82 2000 1000 1003
51. A.M. Eggermont, J.H. de Wilt, and T.L. ten Hagen Current uses of isolated limb perfusion in the clinic and a model system for new strategies Lancet Oncol 4 2003 429 437
52. W.R. Cornett, L.M. McCall, R.P. Petersen, and et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020 J Clin Oncol 24 2006 4196 4201
53. D.L. Fraker, H.R. Alexander, M. Andrich, and et al. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor Cancer J Sci Am 1 1995 122 130
54. F.J. Lejeune, and A.M. Eggermont Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs J Clin Oncol 25 2007 1449 1450 author reply 1450-1
55. J. Wong, Y.A. Chen, K.J. Fisher, and et al. Isolated limb infusion in a series of over 100 infusions: a single-center experience Ann Surg Oncol 20 2013 1121 1127
56. K.K. Turaga, G.M. Beasley, J.M. Kane 3rd, and et al. Limb preservation with isolated limb infusion for locally advanced nonmelanoma cutaneous and soft-tissue malignant neoplasms Arch Surg 146 2011 870 875
57. M.D. Moncrieff, H.M. Kroon, P.C. Kam, and et al. Isolated limb infusion for advanced soft tissue sarcoma of the extremity Ann Surg Oncol 15 2008 2749 2756
58. B.J. Coventry, H.M. Kroon, M.H. Giles, and et al. Australian multi-center experience outside of the Sydney Melanoma Unit of isolated limb infusion chemotherapy for melanoma J Surg Oncol 109 2014 780 785
59. G.M. Beasley, A. Caudle, R.P. Petersen, and et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US J Am Coll Surg 208 2009 706 715 discussion 715-7
60. M.H. Giles, and B.J. Coventry Isolated limb infusion chemotherapy for melanoma: an overview of early experience at the Adelaide Melanoma Unit Cancer Manag Res 5 2013 243 249
61. R. Mian, M.A. Henderson, D. Speakman, and et al. Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion Can J Surg 44 2001 189 192
62. H.M. Kroon, M. Moncrieff, P.C. Kam, and et al. Outcomes following isolated limb infusion for melanoma. A 14-year experience Ann Surg Oncol 15 2008 3003 3013
63. P. Lindner, A. Doubrovsky, P.C. Kam, and et al. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma Ann Surg Oncol 9 2002 127 136
64. M.S. Brady, K. Brown, A. Patel, and et al. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity Ann Surg Oncol 13 2006 1123 1129
65. S. Bonvalot, A. Laplanche, F. Lejeune, and et al. Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better? Ann Oncol 16 2005 1061 1068
66. D.J. Grunhagen, J.H. de Wilt, W.J. Graveland, and et al. The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma Cancer 106 2006 156 162
67. F.J. Lejeune, N. Pujol, D. Lienard, and et al. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities Eur J Surg Oncol 26 2000 669 678
68. E.M. Noorda, B.C. Vrouenraets, O.E. Nieweg, and et al. Safety and efficacy of isolated limb perfusion in elderly melanoma patients Ann Surg Oncol 9 2002 968 974
69. J.P. Deroose, A.M. Eggermont, A.N. van Geel, and et al. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas J Clin Oncol 29 2011 4036 4044
70. S. Bonvalot, F. Rimareix, S. Causeret, and et al. Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoid-type fibromatosis with TNF 1 mg and melphalan (T1-M HILP) is safe and efficient Ann Surg Oncol 16 2009 3350 3357
71. H.R. Alexander Jr., D.L. Fraker, D.L. Bartlett, and et al. Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters J Clin Oncol 28 2010 114 118
72. A.J. Hayes, S.J. Neuhaus, M.A. Clark, and et al. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma Ann Surg Oncol 14 2007 230 238
73. F.J. Lejeune, D. Lienard, S. Leyvraz, and et al. Regional therapy of melanoma Eur J Cancer 29A 1993 606 612
74. D. Lienard, A.M. Eggermont, H.S. Koops, and et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study Melanoma Res 9 1999 491 502
75. D.L. Fraker, H.R. Alexander, M. Andrich, and et al. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study J Clin Oncol 14 1996 479 489
76. A.K. Raymond, G.M. Beasley, G. Broadwater, and et al. Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution J Am Coll Surg 213 2011 306 316
77. F. Grabellus, C. Kraft, S.Y. Sheu-Grabellus, and et al. Tumor vascularization and histopathologic regression of soft tissue sarcomas treated with isolated limb perfusion with TNF-alpha and melphalan J Surg Oncol 103 2011 371 379
78. A.F. Olieman, D. Lienard, A.M. Eggermont, and et al. Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study Arch Surg 134 1999 303 307
79. D.J. Grunhagen, J.H. de Wilt, C. Verhoef, and et al. TNF-based isolated limb perfusion in unresectable extremity desmoid tumours Eur J Surg Oncol 31 2005 912 916
80. J. Larkin, V. Chiarion-Sileni, R. Gonzalez, and et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma N Engl J Med 373 1 2015 Jul 2 23 34
81. M.A. Postow, J. Chesney, A.C. Pavlick, and et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma N Engl J Med 372 2015 2006 2017
82. C. Robert, G.V. Long, B. Brady, and et al. Nivolumab in previously untreated melanoma without BRAF mutation N Engl J Med 372 2015 320 330
83. S.L. Topalian, M. Sznol, D.F. McDermott, and et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab J Clin Oncol 32 2014 1020 1030
84. P.A. Prieto, J.C. Yang, R.M. Sherry, and et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma Clin Cancer Res 18 2012 2039 2047
85. Addition of ipilimumab (MDX-010) to isolated limb infusion with standard melphalan and dactinomycin in the treatment of advanced unresectable melanoma of the extremity 2015 National Library of Medicine Bethesda, MD, USA Available online: http://clinicaltrials.gov/show/NCT00094653 [accessed 10.07.15]
86. R.H. Andtbacka, H.L. Kaufman, F. Collichio, and et al. Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma J Clin Oncol 33 25 2015 Sep 1 2780 2788
87. T.D. Pencavel, M.J. Wilkinson, D.C. Mansfield, and et al. Isolated limb perfusion with melphalan, tumour necrosis factor-alpha and oncolytic vaccinia virus improves tumour targeting and prolongs survival in a rat model of advanced extremity sarcoma Int J Cancer 136 2015 965 976
88. R. Olofsson Bagge, J. Mattsson, and L. Hafstrom Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities-long-term follow-up of a randomised trial Int J Hyperth 30 2014 295 298